SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
SCHEDULE 13D/A5 (Amendment No. 5)
Under the Securities Exchange Act of 1934
Bioject Medical Technologies, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, without par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
0905T-10-7
--------------------------------------------------------------------------------
(CUSIP Number)
William F. Daniel
Elan Corporation, plc
Lincoln House
Lincoln Place
Dublin 2, Ireland
(353) 1-709-4000
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
June 15, 2004
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box [ ].
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 240.13d-7 for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6
--------------------------------------------------------------------------------
CUSIP No. 0905T-10-7
--------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSONS
Elan Corporation, plc
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
N/A
--------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See
Instructions)
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
(3) SEC USE ONLY
--------------------------------------------------------------------------------
(4) SOURCE OF FUNDS WC
--------------------------------------------------------------------------------
(5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Ireland
--------------------------------------------------------------------------------
Number of (7) SOLE VOTING POWER
Shares None
--------------------------------------------------------------
Beneficially (8) SHARED VOTING POWER
Owned 853,122
--------------------------------------------------------------
by Each (9) SOLE DISPOSITIVE POWER
Reporting None
--------------------------------------------------------------
Person With (10) SHARED DISPOSITIVE POWER
853,122
--------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
853,122
--------------------------------------------------------------------------------
(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
[ ]
--------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.1% (based on 13,539,771 shares of Common Stock outstanding
on May 10, 2004, as reported in the quarterly report on
Form 10-Q filed by the Issuer on May 12, 2004, plus 505,334
shares of Common Stock issuable upon exercise of the Warrants)
--------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON CO
--------------------------------------------------------------------------------
Page 2 of 6
--------------------------------------------------------------------------------
CUSIP No. 0905T-10-7
--------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSONS Elan International Services, Ltd.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
N/A
--------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See
Instructions)
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
(3) SEC USE ONLY
--------------------------------------------------------------------------------
(4) SOURCE OF FUNDS WC
--------------------------------------------------------------------------------
(5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
--------------------------------------------------------------------------------
Number of (7) SOLE VOTING POWER
Shares None
--------------------------------------------------------------
Beneficially (8) SHARED VOTING POWER
Owned 853,122
--------------------------------------------------------------
by Each (9) SOLE DISPOSITIVE POWER
Reporting None
--------------------------------------------------------------
Person With (10) SHARED DISPOSITIVE POWER
853,122
--------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
853,122
--------------------------------------------------------------------------------
(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
[ ]
--------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.1% (based on 13,539,771 shares of Common Stock outstanding
on May 10, 2004, as reported in the quarterly report on Form
10-Q filed by the Issuer on May 12, 2004, plus 505,334 shares
of Common Stock issuable upon exercise of the Warrants)
--------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON CO
--------------------------------------------------------------------------------
Page 3 of 6
--------------------------------------------------------------------------------
CUSIP No. 0905T-10-7
--------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSONS Elan Pharmaceutical Investments,
Ltd.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
N/A
--------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See
Instructions)
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
(3) SEC USE ONLY
--------------------------------------------------------------------------------
(4) SOURCE OF FUNDS WC
--------------------------------------------------------------------------------
(5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
--------------------------------------------------------------------------------
Number of (7) SOLE VOTING POWER
Shares None
--------------------------------------------------------------
Beneficially (8) SHARED VOTING POWER
Owned 853,122
--------------------------------------------------------------
by Each (9) SOLE DISPOSITIVE POWER
Reporting None
--------------------------------------------------------------
Person With (10) SHARED DISPOSITIVE POWER
853,122
--------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
853,122
--------------------------------------------------------------------------------
(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
[ ]
--------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.1% (based on 13,539,771 shares of Common Stock outstanding
on May 10, 2004, as reported in the quarterly report on
Form 10-Q filed by the Issuer on May 12, 2004, plus 505,334
shares of Common Stock issuable upon exercise of the Warrants)
--------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON CO
--------------------------------------------------------------------------------
Page 4 of 6
Item 1. Security and Issuer.
Item 1 of Schedule 13D is hereby amended and restated in its entirety as
follows:
This Amendment No. 5 amends the Schedule 13D filed with the Securities and
Exchange Commission (the "Commission") on October 15, 1997, as amended by the
Schedule 13D/A1 filed with the Commission on January 15, 2003, as amended by the
Schedule 13D/A2 filed with the Commission on February 10, 2004 as amended by
Schedule 13D/A3 filed with the Commission on April 5, 2004 and as amended by
Schedule 13D/A4 filed with the Commission on April 21, 2004 (the "Schedule
13D"), by Elan Corporation, plc ("Elan"), Elan International Services, Ltd.
("EIS") and Elan Pharmaceutical Investments, Ltd. ("EPIL"), relating to the
common stock, no par value (the "Common Stock"), of Bioject Medical
Technologies, Inc., an Oregon corporation (the "Issuer"), whose principal
offices are located at 211 Somerville Road (Route 202 North), Bedminster, New
Jersey 07921.
Item 5. Interest in Securities of Issuer.
Item 5 of Schedule 13D is hereby amended and restated in its entirety as
follows:
(a) Elan and EIS (indirectly through their ownership of EPIL) and EPIL
(directly) are the beneficial owners of 853,122 shares of Common Stock,
representing 6.1% of the outstanding shares of Common Stock (based on 13,539,771
shares of Common Stock outstanding on May 10, 2004, as reported in the quarterly
report on Form 10-Q filed by the Issuer on May 12, 2004, plus 505,334 shares of
Common Stock issuable upon exercise of the Warrants).
(b) Elan Corporation, plc and EIS (indirectly through their ownership of
EPIL) and EPIL (directly) each have shared voting and dispositive power over
853,122 shares of Common Stock.
(c) On June 15, 2004, EPIL sold an aggregate of 2,036,148 shares of Common
Stock in open market transactions at a price of $1.96 per share.
(d) None.
(e) Not applicable.
Page 5 of 6
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, the
undersigned certifies that the information set forth in this statement is true,
complete and correct.
Date: June 17, 2004
ELAN CORPORATION, PLC
By: /s/ William Daniel
---------------------------------------
Name: William Daniel
Title: EVP, Company Secretary
ELAN INTERNATIONAL SERVICES, LTD.
By: /s/ Kevin Insley
----------------------------------------
Name: Kevin Insley
Title: President and Chief Financial
Officer
ELAN PHARMACEUTICAL INVESTMENTS, LTD.
By: /s/ Kevin Insley
---------------------------------------
Name: Kevin Insley
Title: President and Chief Financial
Officer
Page 6 of 6